Positive phase 3 psoriasis trial results for Alumis by end of 2024? | Binary | | | 6 months ago | |
Alumis market cap surpasses $1 billion by mid-2025? | Binary | | | 6 months ago | |
Alumis announces secondary offering by mid-2025? | Binary | | | 6 months ago | |
Alumis stock price by end of 2024? | Categorical | | | 6 months ago | |
Status of Alumis' TYK2 inhibitor phase 3 trial by end of 2024? | Categorical | | | 6 months ago | |
Alumis' next major funding round amount by mid-2025? | Categorical | | | 6 months ago | |
Will Alumis IPO raise at least $300 million? | Binary | | | 6 months ago | |
Will Alumis reach $1 billion valuation within 3 months post-IPO? | Binary | | | 6 months ago | |
Will Alumis TYK2 inhibitor pass phase 3 psoriasis trials by end of 2024? | Binary | | | 6 months ago | |
What will be Alumis' valuation within 3 months post-IPO? | Categorical | | | 6 months ago | |
What will be the outcome of Alumis TYK2 inhibitor's phase 3 psoriasis trial by end of 2024? | Categorical | | | 6 months ago | |
How will Alumis' stock perform within 6 months post-IPO? | Categorical | | | 6 months ago | |
